Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors

Background Enfortumab vedotin (EV), an antibody–drug conjugate targeting Nectin-4, has been used for patients with metastatic urothelial carcinoma (mUC) after progressing on checkpoint inhibitors (CPIs). Re-challenging chemotherapy with platinum agents and continuing CPIs beyond progressive disease...

Full description

Saved in:

Bibliographic Details
Published in:	Targeted oncology Vol. 19; no. 3; pp. 401 - 410
Main Authors:	Uchimoto, Taizo, Tsuchida, Shuya, Komura, Kazumasa, Fukuokaya, Wataru, Adachi, Takahiro, Hirasawa, Yosuke, Hashimoto, Takeshi, Yoshizawa, Atsuhiko, Saruta, Masanobu, Hashimoto, Mamoru, Higashio, Takuya, Matsuda, Takuya, Nishimura, Kazuki, Tsujino, Takuya, Nakamura, Ko, Fukushima, Tatsuo, Nishio, Kyosuke, Yamamoto, Shutaro, Iwatani, Kosuke, Urabe, Fumihiko, Mori, Keiichiro, Yanagisawa, Takafumi, Tsuduki, Shunsuke, Takahara, Kiyoshi, Inamoto, Teruo, Miki, Jun, Fujita, Kazutoshi, Kimura, Takahiro, Ohno, Yoshio, Shiroki, Ryoichi, Uemura, Hirotsugu, Azuma, Haruhito
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01-05-2024 Springer Nature B.V
Subjects:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Biomedicine Cancer Carcinoma, Transitional Cell - drug therapy Chemotherapy Clinical outcomes Female Humans Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Male Medicine Medicine & Public Health Metastasis Middle Aged Neoplasm Metastasis Oncology Original Research Article Retrospective Studies Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urologic Neoplasms - drug therapy Urologic Neoplasms - pathology Urological cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!